Recent Advances in Vitiligo Treatment

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Vitiligo is a chronic autoimmune condition characterized by depigmentation.
• Current treatments aim to restore melanocytes and improve cosmetic outcomes.
• Advances in understanding the immune pathogenesis of vitiligo drive therapeutic innovation.

Purpose of the Study:

• To systematically review breakthrough vitiligo treatment advances from 2020 to 2025.
• To provide evidence-based insights for clinical practice.
• To highlight novel therapeutic strategies and their efficacy.

Main Methods:

• Literature search of ClinicalTrials.gov and PubMed (2020-2025).
• Inclusion of randomized controlled trials (RCTs), Phase II+ clinical trials, and translational research.
• Systematic analysis of treatment outcomes and mechanisms of action.

Main Results:

• Janus kinase (JAK) inhibitors demonstrate significant repigmentation by targeting the IFN-γ/JAK-STAT pathway.
• Novel agents like IL-15 inhibitors selectively eliminate pathogenic T cells.
• Combination therapies (e.g., 308 nm excimer laser with JAK inhibitors or platelet-rich plasma) show enhanced efficacy in acral vitiligo.
• Vitamin D adjunct therapy, ReCell technology with narrowband UVB (NB-UVB), and miniature punch grafting offer additional treatment options.
• Repurposed drugs and antioxidants expand the therapeutic arsenal.

Conclusions:

• Vitiligo treatment has entered an era of precision immune modulation.
• JAK inhibitors are established as first-line therapy, with novel biologics showing promise.
• Combined phototherapy and cellular therapies enhance repigmentation efficiency.
• Drug repurposing contributes to a richer therapeutic landscape.